Get started

Invest

next year target above 49 finalized ?Yes , Now it is consolidating in it's range but once it breaks its trend line with volume and remains there , It wont take time to reach 49+... NOW , FUNDAMENTALS:: Indian Railway Finance Corporation (IRFC) will raise up to Rs 3,000 crore through issuance of unsecured, redeemable, taxable non-convertible debentures (NCD) maturing in 10-year. The NCDs have a base issue of Rs 500 crore, with retain oversubscription of Rs 2,500 crore. I've completed my analysis of IRFC . My target is that it will go down to 23 or 1 or 2 rupees dip more.. rupees in these days if market takes correction otherwise it will start it's rally till 50 rupees. TARGET OF PRICE RALLY IN IRFC FOR 1-2 YEARS Upside target 124.05 Upside target 112.77 Upside target 24.28 Downside Target 23.99 Downside Target 23.64 Downside Target 23.3 Downside Target 23.24 Downside Target 20.92 Bond 8.00% Pa Tax Free S1 IRFC Opened at 24.85 & Closed at 24.15 and moved inside a range of 24.05-24.95 PRICE ALLY IN IRFC FOR LONG TERM NVESTMENT Upside Price target 1224.55 Upside Price target 1165.00 Upside Price target 1151.00 Upside Price target 1140.01 Upside Price target 25.46 Upside Price target 25.11 Upside Price target 24.64 Downside Price target 23.89 GUYS I LOVE THIS STOCK FOR INVESTMENT F YOU WANT TO DOUBLE OR TRIPPLE YOUR MONEY JUST INVEST ALL YOUR MONEY ... (as per your knowledge )
NSE:IRFC
by Abhishek722
15
Tatva Chintan Pharma- China Plus one Theme?Tatva Chintan Pharma- Recent IPO - CMP 2250- Mcap 4989 Cr There is no Margin of Safety Currently in Valuations if i look it as a Long Term bet. However- Currently China Factor is Keeping Speciality Chemical Companies Afloat and Bouyant. As long as sentiments are good, Valuations can go Crazy. Speciality Chemicals can be a good Theme to Trade. Incorporated in 1996, Tatva Chintan Pharma Chem Limited is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals. It is among the largest manufacturer of SDAs for zeolites in India. The company serves customers across industries i.e. automotive, petroleum, agrochemicals, dyes and pigments, paints and coatings, pharmaceutical, personal care, and others. Its products are not only sold in India but also export to 25+ countries all over the world such as the USA, Germany, South Africa, China, and the UK. In FY 2020, total export contributed to 76% of total revenue from operations. Merck, Bayer AG, Ipox Chemicals, Laurus labs, Navin Fluorine International Limited, Atul Limited, Otsuka Chemicals, SRF Limited, Hawks Chemical Company, Firmenich Aromatics Prod Pvt Ltd, and Divi's laboratories are a few of customers of the company. Currently, it has two manufacturing facilities at Ankleshwar and Dahej in Gujarat. Competitive strengths Leading manufacturer of structure directing agents and phase transfer catalyst. Diversified product portfolio. Global market presence with customer base across industries. Strategically located manufacturing facility in Gujarat with close proximity to Hazira Port. Experienced promoters and managers team. Strong financial performance track record. Company Promoters: Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, and Snehkar Rasiklal Somani are the company promoters.
NSE:TATVALong
by StrategicAlpha
Likhitha Infrastructure Ltd - Fundamental and Technical AnalysisLikhitha Infrastructure Ltd is engaged in the business of Pipeline Laying providing comprehensive erection, testing and commissioning of Oil & Gas Pipelines, City Gas Distribution Projects and Operation and Maintenance (O & M) Services. Company’s operations include three principal business lines: (i) Cross Country Pipelines and associated facilities; (ii) City Gas Distribution including CNG Stations; and (iii) Operation & Maintenance of PNG/PNG services. FUNDAMENTALS: > It is a Small Cap company with a market cap of just Rs.868 Cr, very small company. > The ROCE and ROE is at 35% and 26% respectively which is very impressive. Positive. > Stock P/E is at 30 which makes the valuation still attractive as compared to the sector P/E at 59. Positive. > Higher than Industry Revenue Growth: Over the last 5 years, revenue has grown at a yearly rate of 28.6%, vs industry avg of 4.97%. Positive. > Increasing Market Share: Over the last 5 years, market share increased from 0.02% to 0.07%. Positive. > Higher than Industry Net Income: Over the last 5 years, net income has grown at a yearly rate of 62.72%, vs industry avg of 26.93%. Positive. > Very robust Topline and Bottomline, continuously increasing on YoY basis. Company has delivered good profit growth of 62.74% CAGR over last 5 years. > Debts: The company have Debts of Rs. 0 Cr as per Mar 21 Balance Sheet. This is called completely DEBT Free Company. > Reserves: The company is increasing its cash reserves on YoY basis too, Rs. 134 Cr as per Mar 21 Balance Sheet. > OPM is rapidly growing, which is wonderful, it is at 23% as per Mar 21 Balance Sheet, and if we look at last 5 year average it is at 17.6% that’s wonderful. > Promoters holding is intact at whopping 74.11% that is a good sign, like they trust their own business and staying invested. TECHNICALS: > On the chart stock is continuously in UPTREND since it’s listing in Oct 20. > Long Volume towers as indicated by blue arrows at the bottom indicates that lot of accumulation is going on in the stock at almost regular intervals. CLIENTS: ONGC, GAIL, Indian Oil, IGL, HPCL, Torrent Gas, Adani Gas. All big brands in the Gas distribution sector is getting their work done through LIKHITHA. GAS Distribution is the sector of future. Fresh Buy - AT CMP i.e. Rs. 439 Old Buy – Hold Target – Hold for at least 2-3X return. Risk Management Tip: Never invest more than 5% of your capital in any single stock. Happy Investing! ShareMktSchool
NSE:LIKHITHALong
by ShareMarketSchool
2
STOVEKRAFTSwing TrAdE options: After Box Break-Out now forming Descending Triangle Pattern, Depends on the break-Out stock moves further. Current Price- 595 P/E- 23.8 (less among competitors) Short time target: 650, 690 Med Time target: 730(Pole Extension) Pros: Company has reduced debt. Company has delivered good profit growth of 30.97% CAGR over last 5 years Debtor days have improved from 47.73 to 36.00 days. Note: Its revenue contribution was Kitchen Appliances (88%) and Home Appliances (12%) in FY20. The improved product mix resulted in profit expansion. Happy Trading Abd
NSE:STOVEKRAFTShort
by TN_ERNMAT
NURECA | IPO Details ....Started @ 15 / FEB /2021 ( Today) 🎯NURECA IPO REVIEW- Introduction to NURECA- -Incorporated on 2nd November 2016 @Delhi. -B2C Home healthcare and wellness product company. -95% Revenue online. -1 manufacturing unit-@Chandigarh. -3 Brands. What does the company do- -company enables people with tools to effectively monitor chronic illness and upgrade their lifestyles. -company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability, and innovative designs. -company tries to provides the home health care sector with innovation. -Nureca company is the first digital company wherein they sell the products through online channel partners such as e-commerce players, distributors, and retailers. The following brands are currently used by the Company- -Dr. Trust: they provide the users to effectively monitor chronic illness and try to upgrade their lifestyle. -Dr. Physio: This brand provides electric massagers, wheelchairs, and walkers. -Trump: This brand provides the Mother and Child Care category. NURECA PRODUCTS- -Chronic Device Products- products such as blood pressure monitors, pulse oximeters, thermometers, nebulizers, self-monitoring glucose devices, humidifier ands teamers. -Orthopedic Products-such as wheelchairs, walkers and physiotherapy electric massagers. -Mother and Child Products- such as breast pumps, bottle sterilizers, bottle warmers, car seats and baby carrycots. -Nutrition Supplements- such as fish oil, multivitamins, probiotics, biotin, apple cider and vinegar. -Lifestyle Products- such as smart scales, aroma diffusers and fitness trackers. NURECA'S Strength- -Most of the products of NURECA is outsourced. -Due to this their cost of production is low comparatively. -Asset light model. -It increased the production capacity. -Bring product on semi-knocked down condition. -V-shaped recovery. -Nureca has a strong portfolio of products and a consistent focus on quality and innovation. Financial Analysis- -It has grown at a CAGR of 122.49%. As for the total assets, that has grown at a CAGR of 117.12%. -The profits after tax, the growth rate is more moderate. -Over the past three years, the net income has grown at a CAGR of 41.42%. -The negative net cash flow from operating activities has grown at a CAGR of above 780%. -the increasing burden of long-term debt. From Rs. 43 lakhs in 2019 to Rs. 9.77 crores in 2020 is an increase of over 2000%. -If this debt burden continues to increase at this rate, it will create pressure on Nureca’s balance sheet. -It was valued at Rs. 20,757 crores in 2019. By 2025, this market is expected to grow to Rs. 38,920.70 crores. -It has grown from $24 billion in 2017 to $84 billion in 2021. -In India especially, at least 33% of the population resorts to online shopping as opposed to conventional shopping outlets. -Nutritional products, Rs. 17,840 crores in 2019 and it is expected to grow to Rs. 33,368 crores in 2025. -Coming to the market for orthopedic products, in 2019, it was sized at Rs. 682.80 crores. This is expected to grow to Rs. 1,162.90 crores by 2025. The predicted CAGR, in this case, is 9.2%. The graph below shows the growing market size over the years. -The demand for chronic disease products is, of course, fairly inelastic in nature. -Owing to the steadily increasing wave of chronic diseases, this demand is expected to rise in the future. -By 2026, 12.5% of the population is expected to be geriatric in nature i.e. they will be above the age of 60. This means the demand for health-care products will only increase. Business model- -Nureca is a B2C company engaged in the business of home healthcare and wellness products, -it offers quality, durability, functionality, usability and innovative designs. -Voltas enables their customers with tools to help them monitor chronic illness and other diseases, to upgrade their lifestyle. Risk- -it faces stiff competition from organized and unorganized players, which leads to pricing pressure. -it reduced margins and lower profitability. -Home-health products are considered consumer-grade, due to concerns regarding the accuracy measures of products. -The company does not enter into long-term contracts for the manufacturing of its products and any manufacturing-related disruption could seriously impact its business -The company also depends heavily on its channel partners such as third-party e-commerce players, distributors, and retailers. Any failure to manage the distribution network efficiently will adversely affect its performance. IPO details- IPO Date February 15, 2021 to February 17, 2021 Issue Type Book Built Issue IPO Issue Size Rs.100 Crore Fresh Issue Rs.100 Crore Face Value Rs.10 per equity share IPO Price Rs.396 to Rs.400 per equity share Market Lot 35 shares MinOQ 35 shares Listing At BSE, NSE Promoter's holding- -Saurabh Goyal 46.67% -Payal Goyal 46.67% Object of the issue- -To meet the working capital requirements of the business. -To meet the general corporate purpose. 🙏FOLLOW for more ! 👍LIKE if think is useful ! ✍COMMENT Below your view !
NSE:RELIANCEEducation
by ReviveTraders
11